Unlocking The Power Of Advanced Analytics In Life Sciences

2021 was a challenging year, but the life science industry still managed some notable achievements. With COVID vaccines and therapies taking priority it isn’t surprising that Deloitte’s annual estimate of the return on investment that a cohort of the top biopharma companies might expect from their late-stage pipelines has increased from 2.7% in 2020 to 7% in 2021. Even if you exclude COVID-related assets, however, the projected average internal rate of return (IRR) is still 3.2%, an uptick from the previous year that’s due in part to decreasing R&D costs and cycle times.

Read up on some of the exciting ideas being explored in the life science industry, and how the world’s first biopharma life cycle management (BPLM) platform came to be.